This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stuart M. Goldsmith, MD; Elizabeth F. Sherertz, MD
Department of Dermatology

Bayard L. Powell, MD; David D. Hurd, MD
Department of Hematology/Oncology Bowman Gray School of Medicine of Wake Forest University Medical Center Boulevard Winston-Salem, NC 27157-1071

Arch Dermatol. 1991;127(12):1847-1848.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—5-Azacitidine is a pyrimidine analog that has demonstrated activity as an antileukemic agent and as a treatment for some hemoglobinopathies.¹ It has been investigated as a treatment modality for myelodysplastic syndromes (Cancer and Leukemia Group B [CALG B] Protocol 8921: A Phase II Study of 5-Azacitidine in Myelodysplastic Syndromes). In previous studies, no cutaneous complications

have been reported from the subcutaneous administration of 5-azacitidine.²

We describe two patients with myelodysplastic syndromes in whom reproducible cutaneous reactions developed at injection sites of subcutaneous 5-azacitidine.

Report of Cases.

—Case 1.—A 45-year-old white man was hospitalized for treatment of refractory anemia with excess blast forms in transformation. Chemotherapy had been started with 5-azacitidine given at a dose of 180 mg/d divided into two subcutaneous injection sites for a scheduled 7-day course. No other chemotherapy was being administered. On the third day of treatment, it was noted that the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?